

ACC 2011 and i2 Summit

Late-Breaking Clinical Trials



Late-Breaking Clinical Trials I

ACC/i2 Joint Session

Sunday, April 3, 2011, 8:00–10:05 am

Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle

Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement in "High Risk" Patients with Aortic Stenosis: The Randomized PARTNER Trial

Craig R Smith, Columbia University, New York, NY

9:15–9:30 am

Panel discussion

9:30 am– 9:45 am

Lifetime Cost Effectiveness of Transcatheter Aortic Valve Implantation Compared with Standard Care among Inoperable Patients with Severe Aortic Stenosis: Results from the Randomized PARTNER Trial (Cohort B)

Matthew R Reynolds, Beth Israel Deaconess Medical Center, Boston, MA

9:45 am– 9:57 am

Panel discussion

9:57–10:05 am

Late-Breaking Clinical Trials II

ACC/i2 Joint Session

Monday, April 4, 2011, 8:00–9:30 am

Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle

Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease (PRECOMBAT) trial

Seung-Jung Park, Asan Medical Center, Seoul, South Korea

8:00–8:17 am (presentation and panel discussion)

EVEREST II Randomized Clinical Trial: Two Year Outcomes

Ted Feldman, Evanston Northwestern Healthcare, Evanston, IL

8:17–8:34 am (presentation and panel discussion)

Medical Therapy with or without Coronary Artery Bypass Graft Surgery in Patients with Ischemic Cardiomyopathy: Results of the Surgical Treatment of Ischemic Heart Failure Trial

Eric J Velazquez, Duke University, Durham, NC

8:34–8:51 am (presentation and panel discussion)

Influence of Myocardial Viability on Outcome of Patients with Coronary Artery Disease and Left Ventricular Dysfunction Undergoing Medical Therapy with and without Surgical Revascularization: Results of the Surgical Treatment for Ischemic Heart Failure Trial

Robert O Bonow, Northwestern University Medical School, Chicago, IL

8:51–9:08 am (presentation and panel discussion)

Radial Artery and Saphenous Vein Patency More than Five Years Following Coronary Artery Bypass Surgery: Results from the Randomized Multicentre Radial Artery Patency Study (RAPS)

Stephen E Fremes, Sunnybrook Health Sciences Centre, Toronto, ON

9:08–9:25 am (presentation and panel discussion)

Late Breaking Clinical Trials III: Interventional Cardiology

ACC/i2 Joint Session

Monday, April 4, 2011, 10:45 am–12:15 pm

Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle

Long-Term Outcomes after Use of Drug-Eluting Stents and Bare Metal Stents for the Treatment of Saphenous Vein Graft Lesions: Results of the Randomized ISAR-CABG Trial

Julinda Mehilli, Deutsches Herzzentrum, Munich, Germany

10:45–11:03 am (presentation and panel discussion)

Rival Trial: A Randomized Comparison of Radial versus Femoral Access for Coronary Angiography or Intervention in Patients with Acute Coronary Syndromes

Sanjit S Jolly, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, ON

11:03–11:21 am (presentation and panel discussion)

One Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study

Martin B Leon, Columbia University Medical Center, New York City, NY

11:21–11:39 am (presentation and panel discussion)

A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial

Gregg W Stone, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY

11:39–11:57 am (presentation and panel discussion)

Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): Renalguard System In High-risk Patients For Contrast-induced Acute Kidney Injury

Carlo Briguori, Clinica Mediterranea, Naples, Italy

11:57–12:15 pm (presentation and panel discussion)

Late-Breaking Clinical Trials IV

ACC/i2 Joint Session

Tuesday, April 5, 2011, 8:00–9:30 am

Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle

Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

Alexander Cohen, Bayer HealthCare AG, Leverkusen, Germany

8:00–8:17 am (presentation and panel discussion)

The Comparison of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy versus Combination Therapy of ARB with Calcium Channel Blocker on Cardiovascular Events in Japanese Elderly High-Risk Hypertensive Patients: Olmesartan and Calcium Antagonists Randomized (OSCAR) Study

Hisao Ogawa, Kumamoto University, Kumamoto, Japan

8:17–8:34 am (presentation and panel discussion)

Comparison between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients with Glucose Intolerance (NAGOYA HEART Study)

Toyoaki Murohara, Nagoya University School of Medicine, Nagoya, Japan

8:34–8:51 am (presentation and panel discussion)

Selective Inhibition of Delta Protein Kinase C to Reduce Infarct Size after Primary Percutaneous Intervention for Acute Myocardial Infarction: The PROTECTION-AMI Phase IIb Clinical Trial

A Michael Lincoff, Cleveland Clinic, Cleveland, OH

8:51–9:08 am (presentation and panel discussion)

The Randomized Comparison of Six-Month versus 12-Month Duration of Dual Antiplatelet Therapy after Implantation of Drug Eluting Stent: From Comparison of Everolimus versus Sirolimus-Eluting Stents for Coronary Revascularization (EXCELLENT) Trial

Hyeon-Cheol Gwon, Samsung Medical Center, Seoul, South Korea

9:08–9:25 am (presentation and panel discussion)